Salud financiera de hoja de balance de H. Lundbeck

Salud financiera controles de criterios 5/6

H. Lundbeck tiene un patrimonio de accionistas total de DKK22.0B y una deuda total de DKK3.7B, lo que sitúa su ratio deuda-patrimonio en 16.8%. Sus activos y pasivos totales son DKK37.4B y DKK15.4B respectivamente. El BAIT de H. Lundbeck es de DKK3.3B, por lo que su ratio de cobertura de intereses es de -102. Tiene efectivo e inversiones a corto plazo que ascienden a DKK5.0B.

Información clave

16.8%

Ratio deuda-patrimonio

kr.3.71b

Deuda

Ratio de cobertura de intereses	-102x
Efectivo	kr.5.01b
Patrimonio	kr.22.05b
Total pasivo	kr.15.36b
Activos totales	kr.37.41b

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (DKK13.3B) de HLUN A superan a sus pasivos a corto plazo (DKK8.0B).

Pasivo a largo plazo: Los activos a corto plazo de HLUN A (DKK13.3B) superan a sus pasivos a largo plazo (DKK7.4B).

Historial y análisis de deuda-patrimonio

Nivel de deuda: HLUN A tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de HLUN A ha crecido de 0.5% a 16.8% en los últimos 5 años.

Cobertura de la deuda: La deuda de HLUN A está bien cubierta por el flujo de caja operativo (109.9%).

Cobertura de intereses: HLUN A gana más intereses de los que paga, por lo que la cobertura de pagos de intereses no es preocupante.

Hoja de balance

Descubre empresas con salud financiera

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Salud financiera de hoja de balance de H. Lundbeck

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

Full year 2023 earnings released

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

Take Care Before Diving Into The Deep End On H. Lundbeck A/S (CPH:HLUN A)

Third quarter 2023 earnings released

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

Second quarter 2023 earnings released: EPS: kr.0.60 (vs kr.0.51 in 2Q 2022)

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Announces New Data Confirming Long-Term Benefit of Treatment with Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S and Otsuka Pharmaceutical, Co. Ltd. Announce U.S. Food and Drug Administration Approval of sNDA for Rexulti®? (Brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

First quarter 2023 earnings released: EPS: kr.0.89 (vs kr.0.41 in 1Q 2022)

Full year 2022 earnings: Revenues in line with analyst expectations

H. Lundbeck A/S Proposes Dividend for 2022

Investor sentiment improves as stock rises 15%

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia

H. Lundbeck's (CPH:HLUN A) Soft Earnings Are Actually Better Than They Appear

Less than half of directors are independent

Third quarter 2022 earnings released

H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023

H. Lundbeck A/S, Annual General Meeting, Mar 21, 2023

H. Lundbeck A/S (Lundbeck)Announces Positive Data Showing Trintellix/Brintellix® (vortioxetine)

Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month, Ready-To-Use, Long-Acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults

Second quarter 2022 earnings released: EPS: kr.0.51 (vs kr.1.90 in 2Q 2021)

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2022

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2022

Getting In Cheap On H. Lundbeck A/S (CPH:HLUN A) Is Unlikely

H. Lundbeck A/S and Otsuka Pharmaceutical Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer's Dementia Treated with Brexpiprazole

European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole

H. Lundbeck A/S Announces Results from the Deliver Study with Vyepti

Less than half of directors are independent

H. Lundbeck A/S(CPSE:LUN) dropped from OMX Nordic All-Share Index

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Descubre empresas con salud financiera